BASH-001
Chronic Kidney Disease
PreclinicalActive
Key Facts
About Bash Biotech
Bash Biotech is a private, preclinical-stage biotech based in San Francisco, applying a dual-platform approach of AI/ML and systems biology to decode host-microbiome interactions for therapeutic discovery. The company has a nascent pipeline targeting major unmet needs in chronic kidney disease, kidney cancer, Alzheimer's, and Parkinson's disease, all in preclinical development. Founded with $1M in seed funding, it is pre-revenue and focuses on building its proprietary data platforms (iNetModels, GutMicroNet) to drive its drug repositioning and target identification efforts.
View full company profileTherapeutic Areas
Other Chronic Kidney Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| XGal-3® Apheresis Column | Eliaz Therapeutics | Research |
| Undisclosed CKD Program | Averoa | Pre-clinical |
| Platform Application - CKD | MultiOmic Health | Discovery |